Dosage regimen of anti-CD19 agents and uses thereof
The use of three specific agents of anti-CD19 x anti-CD3 x anti-CD2 has solved the challenge of treatment of recurrent and refractory B-cell malignant tumors, especially for patients who are not suitable for traditional therapies, significantly improving the therapeutic effect and survival.
Patent Information
- Application Number
- CN202380031441.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-14
- Filing Date
- 2023-04-12
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art is difficult to effectively treat recurrent and refractory B-cell malignant tumors, especially for patients who are not suitable or unable to receive autologous stem cell transplantation and CAR-T therapy, with high unmet medical needs and low overall survival. .
Using anti-CD19 x anti-CD3 x anti-CD2 three-specific agent, the specific attack of T cells on B cell malignant tumors by targeting CD19, CD3 and CD2 molecules is used to treat recurrent and refractory B cell malignant tumors. , including DLBCL, ALL and other types.
It significantly improves the therapeutic effect of recurrent and refractory B-cell malignant tumors, extends patient survival, and provides effective treatment options for specific patient populations, especially those who are unable to receive traditional therapies.
Smart Images

Figure BDA0005064546770000191 
Figure BDA0005064546770000231 
Figure BDA0005064546770000241
Abstract
Description
1. Technical Field
[0001] The present disclosure generally relates to dosage regimens of anti-CD19 agents, particularly anti-CD19xanti-CD3xanti-CD2 trispecific agents, administered intravenously (iv) and subcutaneously (sc), and their use for treating diseases and disorders associated with the expression of CD19, such as B-cell malignancies, particularly relapsed and / or refractory B-cell malignancies. 2. Background technology
[0002] B cells express a variety of cell surface molecules during differentiation and proliferation. CD19 is a pan-B cell membrane glycoprotein that is expressed early in pre-B cell development through terminal differentiation, thereby regulating the development and function of B lymphocytes. CD19 expression has been identified in the vast majority of non-Hodgkin lymphomas (NHL) and leukemias, including chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and Waldenstrom's macroglobulinemia (WM).
[0003] The prognosis of patients with relapsed and / or refractory (R / R) NHL who have failed treatment after initial therapy is poor. About 50% of patients respond to initial salvage therapy and then undergo allogeneic stem cell transplantation (ASCT), with an overall cure rate of 25% to 35%. Patients who are not ASCT candidates due to poor fitness or concurrent medical conditions, patients who do not respond to salvage therapy, and patients who relapse after ASCT are classified as unsuitable for transplantation. Ultimately, most R / R NHL patients belong to this category, and sequential single-agent chemotherapy or multi-agent regimens with acceptable side effect characteristics are often used for palliative purposes, such as rituximab, gemcitabine, and oxaliplatin (R-GemOx).
[0004] Despite advances in the treatment of R / R ALL, disease recurrence and relapse in patients with increasingly refractory disease remain a major obstacle. Treatment options for patients with R / R ALL remain limited and include high-dose chemotherapy with subsequent stem cell transplantation (SCT), standard chemoimmunotherapy, therapies directed against CD19 or CD22 (blinatumomab, inotuzumab ozogamicin), targeted therapy using small molecule pathway inhibitors, or supportive care with non-curative palliative goals, but remissions are typically of short duration.
[0005] NHL is sometimes classified as immature lymphoid neoplasms, mature B-cell neoplasms, T-cell and natural killer (NK) cell neoplasms, and post-transplant lymphoproliferative disorders (PTLD). Mature B-cell lymphomas can be further classified into indolent lymphomas (e.g., follicular lymphoma, small lymphocytic lymphoma, marginal zone lymphoma) and aggressive lymphomas (e.g., diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL)).
[0006] DLBCL is the most common aggressive lymphoma subtype, accounting for 30%-35% of all NHLs (Ghielmini et al. 2013). Approximately one-third of patients with DLBCL will develop relapsed and / or refractory (R / R) disease, which is a major cause of morbidity and mortality. Relapsed and refractory patients have a poor prognosis. In the SCHOLAR-1 study, which combined data from two clinical trials as well as two academic databases, the median overall survival of 636 patients with refractory DLBCL was only 6.3 months, and only 20% of patients were alive after 2 years (Crump et al. 2017).
[0007] Follicular lymphoma (FL) is the second most common type of NHL. It is the most common clinically indolent NHL, defined as those lymphomas for which the survival of untreated patients is measured in years. The vast majority of patients treated for FL will have an initial response to therapy, with 40%-80% of patients demonstrating a complete response depending on the initial regimen used. However, conventional therapies for FL are not curative, and the majority of these patients eventually develop progressive disease. For patients with R / R FL, unmet medical needs remain high.
[0008] Acute lymphoblastic lymphoma (ALL) is characterized by the accumulation of malignant lymphoblasts in the bone marrow, peripheral circulation, and lymphoid organs. Blinatumomab is a CD19-CD3 bispecific T cell engager approved for the treatment of ALL. However, treatment with blinatumomab lacks durable responses and is characterized by a high relapse rate. Von Stackelberg et al., 2016, Journal of Clinical Oncology 34(36):4381-4389. In addition, blinatumomab has a short half-life, which requires sustained drug exposure to achieve adequate efficacy and manageable toxicity. Porter et al., 2013, Clin Pharmacol. 5(Suppl 1):5-11.
[0009] Despite significant advances in cancer therapy, B-cell malignancies (such as the B-cell subtype of non-Hodgkin lymphoma) are the leading cause of cancer-related deaths. In particular, patients with R / R B-NHL and R / R B-ALL who have failed multiple lines of previous therapy have high unmet medical needs. For patients with R / R DLBCL who are not suitable for or cannot obtain autologous stem cell transplantation (ASCT) and CAR-T therapy, the unmet medical needs remain high. These patients have few effective treatment options and significantly reduced overall survival (OS). For patients who relapse after transplantation or CAR-T therapy, the unmet needs are also high. Therefore, further therapeutic agents are still needed to treat certain B-cell malignancies. 3. Summary of the invention
[0010] In some embodiments, the invention relates to a method of treating a subject having a B cell malignancy by administering an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent. In some embodiments, the invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in treating a B cell malignancy. The B cell malignancy may be a relapsed and / or refractory B cell malignancy. The B cell malignancy may be selected from the group consisting of: R / R LBCL, R / R DLBCL, R / R HGBCL, R / R PMBCL, R / R FL, R / R FL3B, R / R MCL, R / R SLL, R / R MZL, and R / R ALL.
[0011] In some embodiments, the present invention relates to a method of treating a subject with a CD19-related disease or disorder by administering an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent. In some embodiments, the present invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in treating a CD19-related disease or disorder. The CD19-related disease or disorder may be a relapsed and / or refractory disease or disorder. The CD19-related disease or disorder may be selected from the group consisting of: R / R LBCL, R / R DLBCL, R / R HGBCL, R / R PMBCL, R / R FL, R / R FL3B, R / R MCL, R / R SLL, R / R MZL, and R / R ALL. In some embodiments, the CD19-related disease or disorder is systemic lupus erythematosus (SLE).
[0012] In some embodiments, an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may comprise a CD19 binding portion wherein CDR-H1, CDR-H2, and CDR-H3 have the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, and CDR-L1, CDR-L2, and CDR-L3 have the amino acid sequences of SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19.
[0013] In some embodiments, the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may comprise (a) a first polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO: 37; (b) a second polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO: 38; and (c) a third polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO: 39. In some embodiments, the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent comprises the amino acid sequence given in Table 5.
[0014] In some embodiments, the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may comprise (a) a first polypeptide encoded by a nucleotide sequence comprising the sequence of SEQ ID NO: 40; (b) a second polypeptide encoded by a nucleotide sequence comprising the sequence of SEQ ID NO: 41; and (c) a third polypeptide encoded by a nucleotide sequence comprising the sequence of SEQ ID NO: 42. In some embodiments, the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent is encoded by any one of the nucleotide sequences given in Table 6.
[0015] In some embodiments, the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent comprises any one of the sequences given in Tables 1 to 6. In some embodiments, the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent is CD19TSP1.
[0016] In some embodiments, the present invention relates to a method for treating a subject with a B cell malignancy by administering a trispecific antibody. In some embodiments, the present invention relates to a trispecific antibody for use in treating a B cell malignancy. The B cell malignancy may be a recurrent and / or refractory B cell malignancy. In some embodiments, the trispecific antibody may comprise (a) a first polypeptide, the amino acid sequence of which comprises the amino acid sequence of SEQ ID NO: 37; (b) a second polypeptide, the amino acid sequence of which comprises the amino acid sequence of SEQ ID NO: 38; and (c) a third polypeptide, the amino acid sequence of which comprises the amino acid sequence of SEQ ID NO: 39. In some embodiments, the trispecific antibody comprises the amino acid sequence given in Table 5. The B cell malignancy may be selected from the group consisting of LBCL, DLBCL, HGBCL, PMBCL, FL, FL3B, MCL, SLL, MZL and ALL. The B-cell malignancy may be selected from the group consisting of R / R LBCL, R / R DLBCL, R / R HGBCL, R / R PMBCL, R / R FL, R / R FL3B, R / R MCL, R / R SLL, R / R MZL and R / R ALL.
[0017] In some embodiments, the present invention relates to a method of treating a subject having a disorder selected from LBCL, DLBCL, HGBCL, PMBCL, FL, FL3B, MCL, SLL, MZL and ALL, the method comprising administering to the subject a therapeutically effective amount of an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent. In some embodiments, the present invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in treating a disorder selected from LBCL, DLBCL, HGBCL, PMBCL, FL, FL3B, MCL, SLL, MZL and ALL. In some embodiments, the present invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in treating a disorder selected from LBCL, DLBCL, HGBCL, PMBCL, FL, FL3B, MCL, SLL, MZL, ALL and SLE. In some embodiments, the disorder is LBCL or FL3B, optionally relapsed and / or refractory LBCL or FL3B. In some embodiments, the disorder is an autoimmune disorder, optionally systemic lupus erythematosus (SLE).
[0018] In some embodiments, the present invention relates to a method of treating a subject with non-Hodgkin lymphoma (NHL) by administering an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent to a subject in need thereof. The NHL may be relapsed and / or refractory NHL. The NHL may be relapsed and / or refractory B-cell non-Hodgkin lymphoma (R / R B-NHL). In some embodiments, the present invention relates to a method of treating a subject with B-cell lymphoma (LBCL) by administering an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent to a subject in need thereof. The LBCL may be relapsed and / or refractory LBCL. In some embodiments, the present invention relates to a method of treating a subject with diffuse large B-cell lymphoma (DLBCL) by administering an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent to a subject in need thereof. The DLBCL may be relapsed and / or refractory DLBCL. The DLBCL may be de novo or transformed. In some embodiments, the present invention relates to a method for treating a subject with high-grade B-cell lymphoma by administering an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent to a subject in need thereof. The lymphoma may be a double / triple hit high-grade B-cell lymphoma (HGBCL). The HGBCL may be relapsed and / or refractory HGBCL. The HGBCL may be a relapsed and / or refractory double / triple hit HGBCL. In some embodiments, the present invention relates to a method for treating a subject with primary mediastinal large B-cell lymphoma (PMBCL) by administering an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent to a subject in need thereof. The PMBCL may be a relapsed and / or refractory PMBCL. In some embodiments, the present invention relates to a method for treating a subject with follicular lymphoma (FL) by administering an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent to a subject in need thereof. FL may be a relapsed and / or refractory FL. In some embodiments, the present invention relates to a method of treating a subject with grade 3B follicular lymphoma (FL3B) by administering an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent to a subject in need thereof. FL3B may be relapsed and / or refractory FL3B. In some embodiments, the present invention relates to a method of treating a subject with mantle cell lymphoma (MCL) by administering an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent to a subject in need thereof. MCL may be relapsed and / or refractory MCL. In some embodiments, the present invention relates to a method of treating a subject with small lymphocytic lymphoma (SLL) by administering an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent to a subject in need thereof. SLL may be relapsed and / or refractory SLL.In some embodiments, the present invention relates to a method of treating a subject with (e.g., nodal, extranodal, or mucosa-associated) marginal zone lymphoma (MZL) by administering an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent to a subject in need thereof. The MZL may be relapsed and / or refractory MZL. Optionally, in each of the above cases, the treatment may be after a prior CAR-T therapy (e.g., a CAR-T therapy directed to CD19). In an alternative, the treatment may be without a prior CAR-T therapy, such as a CAR-T therapy directed to CD19. Optionally in each of the above cases, the treatment may be after treatment with a chemotherapy regimen containing a CD20 monoclonal antibody. In addition, optionally in each of the above cases, the treatment may be after a prior autologous hematopoietic stem cell transplant (HSCT). The subject may have an Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to two.
[0019] In some embodiments, the present invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in the treatment of non-Hodgkin lymphoma (NHL). The NHL lymphoma may be relapsed and / or refractory NHL. The NHL may be a relapsed and / or refractory B-cell non-Hodgkin lymphoma (R / R B-NHL). In some embodiments, the present invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in the treatment of large B-cell lymphoma (LBCL). The LBCL may be a relapsed and / or refractory LBCL. In some embodiments, the present invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in the treatment of diffuse large B-cell lymphoma (DLBCL). The DLBCL may be a relapsed and / or refractory DLBCL. The DLBCL may be de novo or transformed. In some embodiments, the present invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in the treatment of high-grade B-cell lymphoma (HGBCL). The lymphoma may be a double / triple hit high-grade B-cell lymphoma (HGBCL). The HGBCL may be relapsed and / or refractory HGBCL. The HGBCL may be relapsed and / or refractory double / triple hit HGBCL. In some embodiments, the present invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in the treatment of primary mediastinal large B-cell lymphoma (PMBCL). The PMBCL may be relapsed and / or refractory PMBCL. In some embodiments, the present invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in the treatment of follicular lymphoma. FL may be relapsed and / or refractory FL. In some embodiments, the present invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in the treatment of grade 3B follicular lymphoma (FL3B). FL3B may be relapsed and / or refractory FL3B. In some embodiments, the present invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in the treatment of mantle cell lymphoma (MCL). MCL may be relapsed and / or refractory MCL. In some embodiments, the present invention relates to an anti-CD19xanti-CD3xanti-CD2 trispecific agent for use in the treatment of small lymphocytic lymphoma (SLL). SLL may be relapsed and / or refractory SLL. In some embodiments, the present invention relates to an anti-CD19 xanti-CD3 xanti-CD2 trispecific agent for use in the treatment of (e.g., nodal, extranodal, or mucosa-associated) marginal zone lymphoma (MZL). MZL may be relapsed and / or refractory MZL. Optionally, in each of the above cases, treatment may be after a prior CAR-T therapy (e.g., a CAR-T therapy for CD19).In alternative selections, treatment may not have previous CAR-T therapy, such as CAR-T therapy for CD19. Optionally in each of the above cases, treatment may be after treatment with a chemotherapy regimen containing a CD20 monoclonal antibody. In addition, optionally in each of the above cases, treatment may be after a previous autologous hematopoietic stem cell transplant (HSCT). Treatment may optionally be used when the subject's Eastern Cooperative Oncology Group (ECOG) performance status may be less than or equal to two.
[0020] In some embodiments, the invention relates to a method of treating a subject with relapsed and / or refractory NHL (e.g., DLBCL, HGBCL, PMBCL, FL, FL3B, MCL, SLL, MZL) by administering an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent to a subject in need thereof, wherein the relapsed and / or refractory NHL may have relapsed after or failed to respond to at least two prior treatment regimens, including a chemotherapy regimen containing an anti-CD20 monoclonal antibody. In some embodiments, the invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in treating relapsed and / or refractory NHL (e.g., DLBCL, HGBCL, PMBCL, FL, FL3B, MCL, SLL, MZL), wherein the relapse and / or refractory may be relapsed after or failed to respond to at least two prior treatment regimens, including a chemotherapy regimen containing an anti-CD20 monoclonal antibody.
[0021] In some embodiments, the present invention relates to a method for treating a subject with relapsed and / or refractory large B-cell lymphoma (DLBCL, HGBCL, PMBCL, FL3B), wherein relapse and / or refractory may include previous failure of autologous hematopoietic stem cell transplantation (HSCT). In some embodiments, the present invention relates to a method for treating a subject with relapsed and / or refractory large B-cell lymphoma (DLBCL, HGBCL, PMBCL, FL3B), wherein the subject is not suitable for or cannot receive autologous stem cell transplantation due to age and / or comorbidity. In some embodiments, the present invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in the treatment of relapsed and / or refractory large B-cell lymphoma (DLBCL, HGBCL, PMBCL, FL3B), wherein relapse and / or refractory may include previous failure of autologous hematopoietic stem cell transplantation (HSCT). In some embodiments, the invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in the treatment of relapsed and / or refractory large B-cell lymphoma (DLBCL, HGBCL, PMBCL, FL3B), wherein the subject is not suitable for or cannot undergo autologous stem cell transplantation due to age and / or comorbidities.
[0022] In some embodiments, the invention relates to a method of treating a subject having NHL (e.g., DLBCL, HGBCL, PMBCL, FL, FL3B, MCL, SLL, MZL) by administering an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent to a subject in need thereof, wherein the subject may have at least one two-dimensionally measurable nodal lesion or one two-dimensionally measurable extranodal lesion as measured on a positron emission tomography-computed tomography (PET / CT) scan. In some embodiments, the invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in treating NHL (e.g., DLBCL, HGBCL, PMBCL, FL, FL3B, MCL, SLL, MZL), wherein the subject may have at least one two-dimensionally measurable nodal lesion or one two-dimensionally measurable extranodal lesion as measured on a positron emission tomography-computed tomography (PET / CT) scan.
[0023] In some embodiments, the present invention relates to a method for treating a subject with acute lymphoblastic leukemia (ALL) by administering a therapeutically effective amount of an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent to a subject in need thereof. ALL may be relapsed and / or refractory ALL. ALL may be relapsed and / or refractory B-cell acute lymphoblastic leukemia (R / R B-ALL). ALL may be relapsed and / or refractory CD19-positive B-ALL. Optionally, the treatment may be after a previous CAR-T therapy for CD19. In an alternative selection, the treatment may not have a previous CAR-T therapy for CD19. In some embodiments, the present invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in the treatment of acute lymphoblastic leukemia (ALL). ALL may be relapsed and / or refractory ALL. ALL may be relapsed and / or refractory B-cell acute lymphoblastic leukemia (R / R B-ALL). ALL may be relapsed and / or refractory CD19-positive B-ALL. Optionally, treatment may be after previous CAR-T therapy for CD19. In an alternative option, treatment may be without previous CAR-T therapy for CD19.
[0024] In some embodiments, the invention relates to a method of treating a subject having acute lymphoblastic leukemia (ALL) wherein morphological disease is present in the bone marrow (≥5% blasts) by administering to a subject in need thereof an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent. In some embodiments, the invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in treating acute lymphoblastic leukemia (ALL) wherein morphological disease is present in the bone marrow (≥5% blasts).
[0025] In some embodiments, the present invention relates to a method of treating a subject with refractory and / or relapsed CD19-positive B-ALL by administering an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent to a subject in need thereof. In some embodiments, the present invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in treating refractory and / or relapsed CD19-positive B-ALL. Refractory and / or relapsed CD19-positive B-ALL may include at least one of the following criteria:
[0026] i) After at least 2 or more lines of systemic therapy
[0027] ii) Relapse or refractory at any time after first salvage therapy, or refractory relapse
[0028] iii) Relapse at any time after hematopoietic stem cell transplantation (HSCT)
[0029] iv) Refractory or intolerant to SOC treatment options (including blinatumomab and inotuzumab), or unsuitable / unable to receive SOC treatment options
[0030] v) Patients have R / R B-ALL Ph+ disease and are intolerant or refractory to available tyrosine kinase inhibitors (TKIs)
[0031] The anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may be administered Q1W or Q2W. The anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may be administered intravenously or subcutaneously. The anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may be administered via an initial priming dose followed by a main dose. The anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may be administered as a lyophilisate.
[0032] The anti-CD19 x anti-CD3 x anti-CD2 trispecific may be administered at 0.1 μg / kg (100 ng / kg) Q1W (optionally intravenously). The anti-CD19 x anti-CD3 x anti-CD2 trispecific may be administered at a dose selected from the group consisting of 0.1, 0.3, 1, 3, 10, 20, 40, 80, 160, 320, 640, 1280, 2560 micrograms / kilogram (μg / kg). The dose is based on the subject's body weight measurement in kg. The anti-CD19 x anti-CD3 x anti-CD2 trispecific may be administered via an initial priming dose (e.g., 80 μg / kg), followed by a main dose of 160 μg / kg.
[0033] In some embodiments, the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may be administered with one or more agents selected from the group consisting of tocilizumab, siltuximab, cyclophosphamide, anti-thymocyte globulin (ATG), alemtuzumab, and anakinra. In some embodiments, the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may be administered with one or more agents selected from the group consisting of steroids, anti-IL-6, anti-TNF, and anti-IL-1R antibodies. In some embodiments, the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may be administered with one or more agents selected from the group consisting of tocilizumab, siltuximab, cyclophosphamide, anti-thymocyte globulin (ATG), alemtuzumab, anakinra, steroids, anti-IL-6, anti-TNF, and anti-IL-1R antibodies. In some embodiments, the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may be administered with one or more agents selected from the group consisting of antihistamines, steroids (including corticosteroids), or other anti-T cell-directed therapies (e.g., tocilizumab or canakinumab). In some embodiments, the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may be administered with tocilizumab and / or corticosteroids. For example, the steroid may be prednisone or dexamethasone. In some embodiments, the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may be administered with CRS therapy.
[0034] In some embodiments, the invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in treating a subject suffering from a disorder selected from the group consisting of: LBCL, DLBCL, HGBCL, PMBCL, FL, FL3B, MCL, SLL, MZL, and ALL, wherein the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may comprise (a) a first polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO: 37; (b) a second polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO: 38; and (c) a third polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO: 39. In some embodiments, the invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in treating a subject suffering from a disorder selected from the group consisting of: R / R LBCL, R / RDLBCL, R / R HGBCL, R / R PMBCL, R / R FL, R / R FL3B, R / R MCL, R / R SLL, R / R MZL, and R / R ALL, wherein the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may comprise (a) a first polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO: 37; (b) a second polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO: 38; and (c) a third polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO: 39. In some embodiments, the present invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in treating a subject with R / R NHL, wherein the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may comprise (a) a first polypeptide having an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 37; (b) a second polypeptide having an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 38; and (c) a third polypeptide having an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 39. In some embodiments, the present invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in treating a subject with R / R ALL, wherein the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may comprise (a) a first polypeptide having an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 37; (b) a second polypeptide having an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 38; and (c) a third polypeptide having an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 39.The anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may be administered Q1 W or Q2 W. The anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may be administered intravenously or subcutaneously. The anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may be administered via an initial priming dose followed by a main dose.
[0035] In some embodiments, the invention relates to a method of treating a subject having a CD19-related disease or disorder, the method comprising administering an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent at a dose selected from the group consisting of 0.1, 0.3, 1, 3, 10, 20, 40, 80, 160, 320, 640, 1280, 2560 micrograms / kilogram (μg / kg).
[0036] In some embodiments, the invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use as a medicament, wherein said anti-CD19 x anti-CD3 x anti-CD2 trispecific agent is administered at a dose selected from the group consisting of 0.1, 0.3, 1, 3, 10, 20, 40, 80, 160, 320, 640, 1280, 2560 micrograms / kilogram (μg / kg).
[0037] In some embodiments, an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may comprise a CD19 binding portion wherein CDR-H1, CDR-H2, and CDR-H3 have the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, and CDR-L1, CDR-L2, and CDR-L3 have the amino acid sequences of SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19.
[0038] In some embodiments, the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent comprises (a) a first polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO: 37; (b) a second polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO: 38; and (c) a third polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO: 39. 3. Description of the drawings
[0039] Figure 1 Diagram showing the structure of an anti-CD19 x anti-CD3 x anti-CD2 trispecific. The anti-CD2 portion is shown as the CD58 portion.
[0040] Figure 2CD19TSP1 mediates dose-dependent killing of Karpas-422 cells
[0041] Figure 3 CD19TSP1 induces dose-dependent T cell proliferation in Karpas-422 and T cell co-culture system
[0042] Figure 4 CD19TSP1 treatment resulted in secretion of IFNγ, IL-2, and TNFα by Karpas422-T cell co-cultures.
[0043] Figure 5 CD19TSP1 exhibits dose-dependent antitumor activity in AdT models with DLBCL xenografts
[0044] Figure 6 CD19TSP1 induces a sustained decrease in peripheral blood B cell counts in cynomolgus monkeys 4. Specific implementation methods
[0045] As used herein, the following terms are intended to have the following meanings:
[0046] Antibody:The term "antibody" as used herein refers to a polypeptide (or group of polypeptides) of the immunoglobulin family that can non-covalently, reversibly and specifically bind to an antigen. For example, a naturally occurring "antibody" of the IgG type is a tetramer comprising at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Each heavy chain consists of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region consists of three domains (CH1, CH2, and CH3). Each light chain consists of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region consists of one domain (abbreviated herein as CL). The VH region and the VL region can be further subdivided into hypervariable regions, called complementary determining regions (CDRs), interspersed with more conservative regions called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant region of the antibody can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system. The term "antibody" includes, but is not limited to, monoclonal antibodies, human antibodies, humanized antibodies, camelid antibodies, chimeric antibodies, bispecific or multispecific antibodies, and anti-idiotype (anti-Id) antibodies (including, for example, anti-Id antibodies for antibodies of the present disclosure). These antibodies may belong to any isotype / type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY) or subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2).
[0047] The light chain and the heavy chain are divided into regions of structural homology and regions of functional homology. The terms "constant" and "variable" are used functionally. In this regard, it should be understood that the variable domains of both the light (VL) chain and the heavy (VH) chain portions determine antigen recognition and specificity. In contrast, the constant domains of the light chain (CL) and the heavy chain (CH1, CH2 or CH3) confer important biological properties such as secretion, transplacental mobility, Fc receptor binding, complement binding, etc. By convention, the farther the constant region domain is from the antigen binding site or amino terminus of the antibody, the larger its number. In wild-type antibodies, the variable region is at the N-terminus and the constant region is at the C-terminus; the CH3 domain and the CL domain actually contain the carboxyl termini of the heavy chain and the light chain, respectively.
[0048] Antibody fragments:As used herein, the term "antibody fragment" of an antibody refers to one or more parts of an antibody. In some embodiments, these parts are part of one or more contact domains of an antibody. In some other embodiments, these parts are antigen binding fragments (which retain the ability to non-covalently, reversibly and specifically bind to an antigen), sometimes referred to herein as "antigen binding fragments", "antigen binding fragments thereof", "antigen binding portions", etc. Examples of binding fragments include, but are not limited to, single-chain Fv (scFv), Fab fragments, monovalent fragments consisting of VL, VH, CL and CH1 domains; F(ab)2 fragments, bivalent fragments comprising two Fab fragments connected by a disulfide bridge at the hinge region; Fd fragments consisting of VH and CH1 domains; Fv fragments consisting of the VL and VH domains of a single arm of an antibody; dAb fragments consisting of the VH domain (Ward et al., 1989, Nature [Nature] 341: 544-546); and isolated complementary determining regions (CDRs). Thus, the term "antibody fragment" encompasses proteolytic fragments of an antibody (eg, Fab and F(ab)2 fragments) and engineered proteins comprising one or more portions of an antibody (eg, scFv).
[0049] Antibody fragments can also be incorporated into single domain antibodies, maxibodies, minibodies, intrabodies, diabodies, triabodies, tetrabodies, v-NARs and biscFvs (see, e.g., Hollinger and Hudson, 2005, Nature Biotechnology 23: 1126-1136). Antibody fragments can be grafted into scaffolds based on polypeptides such as type III fibronectin (Fn3) (see U.S. Pat. No. 6,703,199, which describes fibronectin polypeptide monomers).
[0050] Antibody fragments can be incorporated into single-chain molecules comprising a pair of tandem Fv segments (e.g., VH-CH1-VH-CH1), which together with complementary light chain polypeptides (e.g., VL-VC-VL-VC) form a pair of antigen-binding regions (Zapata et al., 1995, Protein Eng. 8:1057-1062; and U.S. Pat. No. 5,641,870).
[0051] Antibody numbering system: In this specification, unless otherwise stated, references to numbered amino acid residues in antibody domains are based on the EU numbering system (e.g., in Table 1). This system was originally designed by Edelman et al., 1969, Proc. Nat'l Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States] 63:78-85 and by Kabat et al., 1991, in Sequences of Proteins of Immunological Interest [Protein sequences with immunological importance], US Department of Health and Human Services, NIH, USA, has been described in detail.
[0052] the term" Anti-CD19 x Anti-CD3 x Anti-CD2 Trispecific Agents ” refers to an agent (e.g., a therapeutic agent) that targets CD19, CD3, and CD2.
[0053] B-cell malignancies: As used herein, a B cell malignancy refers to the uncontrolled proliferation of B cells. Examples of B cell malignancies include non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, leukemia, and myeloma. For example, the B-cell malignancy can be, but is not limited to, multiple myeloma, chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL), large B-cell lymphoma (LBCL), follicular lymphoma (FL), grade 3B follicular lymphoma (FL3B), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL), marginal zone lymphoma (MZL), Burkitt's lymphoma, lymphoblastic lymphoma (Waldenstrom's macroglobulinemia), hairy cell leukemia, splenic marginal zone B-cell lymphoma, extranodal marginal zone lymphoma (EMZL), nodal marginal zone B-cell lymphoma (NZML), and primary effusion lymphoma.
[0054] cancer : The term "cancer" refers to a disease characterized by the uncontrolled (and often rapid) growth of abnormal cells. Cancer cells can spread locally or through the bloodstream and lymphatic system to other parts of the body. Examples of cancer include B cell malignancies described herein. The term "cancerous B cell" refers to a B cell that is undergoing or has undergone uncontrolled proliferation.
[0055] CD2: The term "CD2" refers to the cluster of differentiation 2 molecule. It can be found on T cells or natural killer cells. CD2 interacts with lymphocyte function-associated antigens CD58 (LFA-3) and CD48 / BCM1 to mediate adhesion between T cells and other cell types. CD2 is associated with the triggering of T cells, and the cytoplasmic domain is associated with signal transduction functions. Human and mouse amino acid and nucleic acid sequences can be found in public databases such as GenBank, UniProt and Swiss-Prot. For example, the amino acid sequence of human CD2 can be found as UniProt / Swiss-Prot accession number P06729, and the nucleotide sequence encoding human CD2 can be found at accession number NM_001767.5.
[0056] CD3 : The term "CD3" or "differentiation cluster 3" refers to the differentiation cluster 3 co-receptor of the T cell receptor. CD3 helps activate cytotoxic T cells (e.g., CD8+ naive T cells) and helper T cells (e.g., CD4+ naive T cells) and is composed of four different chains: a CD3γ chain (e.g., Genbank accession numbers NM_000073 and MP_000064 (human)), a CD3δ chain (e.g., Genbank accession numbers NM_000732, NM_001040651, NP_00732 and NP_001035741 (human)), and two CD3ε chains (e.g., Genbank accession numbers NM_000733 and NP_00724 (human)). The chains of CD3 are highly related cell surface proteins of the immunoglobulin superfamily containing a single extracellular immunoglobulin domain. The CD3 molecule associates with the T cell receptor (TCR) and the ζ chain to form a T cell receptor (TCR) complex, the role of which is to generate activation signals in T lymphocytes. Unless expressly stated otherwise, reference to CD3 in this application may refer to a CD3 co-receptor, a CD3 co-receptor complex, or any polypeptide chain of a CD3 co-receptor complex.
[0057] CD19: The term "CD19" or "differentiation cluster 19" refers to the differentiation cluster 19 protein, which is an antigenic determinant detectable on leukemia precursor cells. Human and mouse amino acid and nucleic acid sequences can be found in public databases such as GenBank, UniProt and Swiss-Prot. For example, the amino acid sequence of human CD19 can be found as UniProt / Swiss-Prot accession number P15391, and the nucleotide sequence encoding human CD19 can be found at accession number NM_001178098. CD19 is expressed on most B-lineage cancers, including, for example, acute lymphoblastic leukemia, chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) and non-Hodgkin's lymphoma. It is also an early marker for B cell progenitors. See, for example, Nicholson et al., 1997, Mol. Immun. 34(16-17): 1157-1165.
[0058] Chimeric Antigen Receptor : The term "chimeric antigen receptor" or alternatively "CAR" refers to a group of polypeptides, typically two polypeptides in the simplest embodiment, which, when in an immune effector cell, provide the cell with specificity for a target cell (typically a cancer cell), and provide intracellular signal generation. In some embodiments, CAR comprises at least an extracellular antigen binding domain, a transmembrane domain, and a cytoplasmic signaling domain (also referred to herein as an "intracellular signaling domain"), which comprises a functional signaling domain derived from a stimulatory molecule and / or a co-stimulatory molecule defined as follows. The group of polypeptides may be adjacent to or not adjacent to each other. When the polypeptides are not adjacent to each other, the group of polypeptides includes a dimerization switch, which can couple these polypeptides to each other in the presence of a dimerization molecule, for example, the antigen binding domain can be coupled to the intracellular signaling domain. CAR molecules are typically administered to a subject by administering immune effector cells (e.g., preferably T cells of the subject's own body) engineered to express CAR molecules.
[0059] combination:As used herein, "combination" administration means that two (or more) different treatments are delivered to the subject during the period when the subject suffers from the disorder, for example, after the subject is diagnosed with the disorder and before the disorder is cured or eliminated or before the treatment is terminated for other reasons. Two or more treatments are delivered. The term "combination" or "combined with..." is not intended to imply that the therapy or therapeutic agent must be administered simultaneously and / or these therapies or therapeutic agents are formulated for delivery together, although these delivery methods are within the scope described herein. The therapeutic agent in the combination can be administered simultaneously with one or more other additional therapies or therapeutic agents, before or after it. These therapeutic agents or treatment regimens can be administered in any order. Typically, each medicament will be administered with a dosage and / or schedule determined for the medicament. It will also be further understood that the additional therapeutic agents used in the combination can be administered together or separately with different compositions. Typically, it is expected that the additional therapeutic agents used in the combination are used at a level that does not exceed the level when they are used alone. In certain embodiments, the level used in the combination will be lower than the level used alone.
[0060] Complementarity determining region:As used herein, the term "complementarity determining region" or "CDR" refers to the sequence of amino acids within the variable region of an antibody that impart antigen specificity and binding affinity. For example, in general, there are three CDRs (e.g., CDR-H1, CDR-H2, and CDR-H3) in each heavy chain variable region, and there are three CDRs (CDR-L1, CDR-L2, and CDR-L3) in each light chain variable region. The precise amino acid sequence boundaries of a given CDR can be determined using any of a number of well-known schemes, including those described by Kabat et al., 1991, "Sequences of Proteins of Immunological Interest," 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD ("Kabat" numbering scheme), Al-Lazikani et al., 1997, JMB 273:927-948 ("Chothia" numbering scheme), and ImMunoGenTics (IMGT) numbering (Lefranc, 1999, The Immunology Bulletin). Immunologist 7:132-136; Lefranc et al., 2003, Dev. Comp. Immunol. 27:55-77 ("IMGT" numbering scheme). For example, for the classical structure, according to Kabat, the CDR amino acid residues in the heavy chain variable domain (VH) are numbered 31-35 (CDR-H1), 50-65 (CDR-H2), and 95-102 (CDR-H3); and the CDR amino acid residues in the light chain variable domain (VL) are numbered 24-34 (CDR-L1), 50-56 (CDR-L2), and 89-97 (CDR-L3). According to Cho hia, the CDR amino acids in VH are numbered as 26-32 (CDR-H1), 52-56 (CDR-H2) and 95-102 (CDR-H3); and the amino acid residues in VL are numbered as 26-32 (CDR-L1), 50-52 (CDR-L2) and 91-96 (CDR-L3). By combining the CDR definitions of both Kabat and Chothia, the CDRs are composed of amino acid residues 26-35 (CDR-H1), 50-65 (CDR-H2) and 95-102 (CDR-H3) in human VH and amino acid residues 24-34 (CDR-L1), 50-56 (CDR-L2) and 89-97 (CDR-L3) in human VL.According to IMGT, the CDR amino acid residues in VH are numbered approximately 26-35 (CDR-H1), 51-57 (CDR-H2), and 93-102 (CDR-H3), and the CDR amino acid residues in VL are numbered approximately 27-32 (CDR-L1), 50-52 (CDR-L2), and 89-97 (CDR-L3) (according to "Kabat" numbering). According to IMGT, the CDR regions of an antibody can be determined using the program IMGT / DomainGap Align.
[0061] ECOG performance status score : As used herein, the term "ECOG performance status score" refers to a subject's score on the Eastern Cooperative Oncology Group (ECOG) performance status score, as described in Oken et al., 1982, Am J Clin Oncol [American Journal of Clinical Oncology] 5(6):649-55. The score can range from 0 to 5:
[0062]
[0063] Effective amount : The term "effective amount" or "therapeutically effective amount" or "pharmaceutically effective amount" means the amount or quantity of an active agent (or combination of agents) sufficient to elicit a desired or desired response when administered to a subject, or in other words, an amount sufficient to elicit a perceptible biological response. The amount preferably relates to an amount that is effective therapeutically or in a broader sense also preventively against the progression of a disease or disorder as disclosed herein. It should be understood that an "effective amount" or "therapeutically effective amount" may vary from subject to subject due to variations in the subject's metabolism of the agent, age, weight, general condition, the condition being treated, the severity of the condition being treated, and the judgment of the prescribing physician.
[0064] Half Antibody : The term "half antibody" refers to a molecule comprising at least one antigen binding module (ABM) or ABM chain, wherein the ABM has the ability to non-covalently, reversibly and specifically bind to an antigen. A half antibody can associate with another molecule comprising an ABM or an ABM chain through, for example, a disulfide bridge or a molecular interaction (e.g., a knob-and-hole interaction between Fc heterodimers). A half antibody can be composed of one polypeptide chain or more than one polypeptide chain (e.g., two polypeptide chains of a Fab). In an embodiment, a half antibody comprises an Fc region.
[0065] An example of a half antibody is a molecule comprising the heavy and light chains of an antibody (e.g., an IgG antibody). Another example of a half antibody is a molecule comprising a first polypeptide comprising a VL domain and a CL domain, and a second polypeptide comprising a VH domain, a CH1 domain, a hinge domain, a CH2 domain, and a CH3 domain, wherein the VL and VH domains form an ABM. Yet another example of a half antibody is a polypeptide comprising a scFv domain, a CH2 domain, and a CH3 domain.
[0066] A half antibody may include more than one ABM, for example a half antibody comprising (in order from N-terminus to C-terminus) a scFv domain, a CH2 domain, a CH3 domain, and another scFv domain.
[0067] A half-antibody may also include an ABM chain that, when associated with another ABM chain in the other half-antibody, forms a complete ABM.
[0068] Single-chain Fab or scFab : The terms "single-chain Fab" and "scFab" mean a polypeptide comprising an antibody heavy chain variable domain (VH), an antibody constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL) and a linker, such that the VH and VL are associated with each other and the CH1 and CL are associated with each other. In some embodiments, the antibody domains and linkers have one of the following orders in the direction from N-terminus to C-terminus: a) VH-CH1-linker-VL-CL, b) VL-CL-linker-VH-CH1, c) VH-CL-linker-VL-CH1 or d) VL-CH1-linker-VH-CL. The linker can be a polypeptide having at least 30 amino acids, for example, between 32 and 50 amino acids. The single-chain Fab is stabilized via a natural disulfide bond between the CL domain and the CH1 domain.
[0069] Single chain Fv or scFv : As used herein, the term "single-chain Fv" or "scFv" refers to an antibody fragment comprising the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. The Fv polypeptide may further comprise a polypeptide linker between the VH and VL domains that enables the scFv to form a desired structure for antigen binding. For a review of scFv, see Plückthun in The Pharmacology of Monoclonal Antibodies, Vol. 113, Rosenburg and Moore, eds., 1994, Springer-Verlag, New York, pp. 269-315.
[0070] Specific (or selective) binding: The term "specific (or selective) binding" to an antigen or epitope refers to a binding reaction that determines the presence of a homologous antigen or epitope in a heterogeneous population of proteins and other biological agents. ABMs also typically have a specific binding affinity of less than 5 x 10 -2 M, less than 10 -2 M, less than 5x 10 -3 M, less than 10 -3 M, less than 5x 10 -4 M, less than 10 -4 M, less than 5x 10 -5 M, less than 10 -5 M, less than 5x 10 -6 M, less than 10 -6 M, less than 5x 10 -7 M, less than 10 -7 M, less than 5x 10 -8 M, less than 10 -8 M, less than 5x 10 -9 M, or less than 10 -9 The dissociation rate constant (KD) (koff / kon) of M, and binds to the target antigen with an affinity at least twice greater than its affinity for binding to a nonspecific antigen (e.g., HSA). Binding affinity can be measured using Biacore, SPR or BLI assays. The term "specific binding" does not exclude cross-species reactivity. For example, an antigen-binding module (e.g., an antigen-binding fragment of an antibody) that "specifically binds" to an antigen from one species can also "specifically bind" to the antigen in one or more other species. Therefore, such cross-species reactivity itself does not change the classification of the antigen-binding module as a "specific" binder. In certain embodiments, an antigen-binding module that specifically binds to a human antigen has cross-species reactivity with one or more non-human mammal species (e.g., primate species (including but not limited to one or more of cynomolgus macaques (Macacafascicularis), common macaques (Macaca mulatta) and pig-tailed monkeys (Macaca nemestrina)) or rodent species (e.g., house mouse (Mus musculus))). In other embodiments, the antigen binding moiety has no cross-species reactivity.
[0071] Subjects : The term "subject" includes humans and non-human animals. Non-human animals include all vertebrates, e.g., mammals and non-mammals, such as non-human primates, sheep, dogs, cows, chickens, amphibians and reptiles. Unless otherwise indicated, the terms "patient" or "subject" are used interchangeably herein.
[0072] Therapeutically effective amountA "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result.
[0073] Treatment :As used herein, the term "treatment" refers to a reduction or alleviation of the progression, severity and / or duration of a disease or disorder (e.g., a B cell malignancy), or the progression, severity and / or duration of one or more symptoms (e.g., one or more discernible symptoms) of a disorder (e.g., CRS) caused by the administration of one or more anti-CD19 agents. Relief. In some embodiments, the term "treatment" refers to the alleviation of at least one measurable physical parameter of the disorder (e.g., the growth of a tumor), which is not necessarily discernible to the patient. In other embodiments, the term "treatment" refers to physically, physiologically, or by both inhibiting the progression of the disorder by, for example, stabilization of discernible symptoms. In some embodiments, the term "treatment" may refer to a reduction or stabilization of tumor size or cancerous cell counts.
[0074] Trispecific binding molecules : The term "trispecific binding molecule" or "TBM" refers to a molecule that specifically binds to three antigens and comprises three or more antigen binding domains. The TBM disclosed herein comprises at least one antigen binding domain that is specific for CD19, at least one antigen binding domain that is specific for CD3, and at least one antigen binding domain that is specific for CD2.
[0075] VH : The term "VH" refers to the variable region of an immunoglobulin heavy chain of an antibody, including the heavy chain of Fv, scFv, dsFv or Fab.
[0076] V L : The term "VL" refers to the variable region of an immunoglobulin light chain (including the light chain of Fv, scFv, dsFv or Fab).
[0077] Anti-CD19 x Anti-CD3 x Anti-CD2 Trispecific Agent
[0078] Disclosed, at least in part, are anti-CD19 x anti-CD3 x anti-CD2 trispecific agents that target CD19+ cells (malignant B cells as well as normal B cells and follicular dendritic cells) and bind CD3 (TCR signaling component) and CD2 (co-stimulatory receptor) on T cells, resulting in redirected T cell toxicity against CD19-positive malignant cells.
[0079] The simultaneous binding of the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent to multiple molecules (CD19 on malignant B cells, the CD3 subunit of the T cell receptor (TCR) complex, and CD2 on T cells) is believed to result in TCR crosslinking and CD2 co-stimulation and subsequent formation of a cytolytic immune synapse, leading to activation of T cells and specific lysis of malignant B cells. Without being bound by theory, engaging CD2 with CD3 is believed to provide a co-stimulatory signal to efficiently activate T cells and result in a durable T cell response. Such a co-stimulatory signal can improve T cell responses to tumors and help overcome the limitations of CD3 bispecific antibodies.
[0080] Sequences associated with anti-CD19 x anti-CD3 x anti-CD2 trispecific agents are given in the table below. Anti-CD19 x anti-CD3 x anti-CD2 trispecific agents and methods for preparing the agents are also disclosed in PCT / US2020 / 033559 (WO / 2020 / 236792), which is incorporated herein by reference. The anti-CD19 x anti-CD3 x anti-CD2 trispecific agent can be the CD3hi TSP1 (H variant) in Table 19C in PCT / US2020 / 033559 (WO / 2020 / 236792), which is incorporated herein by reference. The first half antibody heavy chain comprises CD19 and CD3 binding sequences. The first half antibody light chain comprises a CD19 binding sequence. The second half antibody comprises a CD2 binding sequence (the CD2 binding sequence can be part of a CD58 sequence). See, e.g. Figure 1 See the structure of the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent. The anti-CD2 portion is shown as the CD58 portion.
[0081]
[0082]
[0083]
[0084]
[0085]
[0086]
[0087]
[0088]
[0089]
[0090]
[0091]
[0092]
[0093]
[0094]
[0095] In some embodiments, an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may comprise a CD19 binding portion wherein CDR-H1, CDR-H2, and CDR-H3 have the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, and CDR-L1, CDR-L2, and CDR-L3 have the amino acid sequences of SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16.
[0096] In some embodiments, an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may comprise a CD19 binding portion wherein CDR-H1, CDR-H2, and CDR-H3 have the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, and CDR-L1, CDR-L2, and CDR-L3 have the amino acid sequences of SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19.
[0097] In some embodiments, the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may comprise a CD19 binding portion wherein the VH has the amino acid sequence of SEQ ID NO: 13. The CD19 binding portion may further comprise a VL having the amino acid sequence of SEQ ID NO: 26. The CD19 binding portion may further comprise a VH having the amino acid sequence of SEQ ID NO: 13 and a VL having the amino acid sequence of SEQ ID NO: 26. In some embodiments, the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may comprise a CD19 binding portion comprising any one of the amino acid sequences in Table 1.
[0098] In some embodiments, an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may comprise a CD3 binding portion wherein CDR-H1, CDR-H2, and CDR-H3 have the amino acid sequences of SEQ ID NO:27, SEQ ID NO:28, and SEQ ID NO:29, and CDR-L1, CDR-L2, and CDR-L3 have the amino acid sequences of SEQ ID NO:30, SEQ ID NO:31, and SEQ ID NO:32.
[0099] In some embodiments, an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may comprise a CD3 binding portion comprising a VH having an amino acid sequence of SEQ ID NO: 33. In some embodiments, an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may comprise a CD3 binding portion comprising a VL having an amino acid sequence of SEQ ID NO: 34. In some embodiments, an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may comprise a CD3 binding portion comprising an amino acid sequence of SEQ ID NO: 35. In some embodiments, an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may comprise a CD3 binding portion comprising any one of the amino acid sequences given in Table 2 and / or Table 3.
[0100] In some embodiments, the CD2 binding moiety domain comprises an IgV domain of its natural ligand CD58 that interacts with CD2 (CD58-IgV, also referred to as anti-CD2). In some embodiments, an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may comprise a CD2 binding moiety that is a CD58 moiety. The CD58 moiety may comprise amino acid residues 30-123 of full-length wild-type CD58. In some embodiments, an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may comprise a CD2 binding moiety having an amino acid sequence of SEQ ID NO: 36. In some embodiments, an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may comprise a CD2 binding moiety that comprises any one of the amino acid sequences given in Table 4.
[0101] B-cell malignancies
[0102] The CD19 protein is ubiquitously expressed in the B lymphocyte lineage. CD19 expression is maintained in B lineage cells that have undergone neoplastic transformation to ALL and B-NHL (Scheumermann and Racila 1995).
[0103] In some embodiments, the B cell malignancy is B cell acute lymphoblastic leukemia (also known as B cell acute lymphoblastic leukemia or B cell acute lymphoid leukemia) (ALL or B-ALL), such as relapsed and / or refractory B-ALL.
[0104] In some embodiments, the present invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in the treatment of relapsed and / or refractory B-NHL. In some embodiments, the present invention relates to a method of treating a subject with relapsed and / or refractory LBCL by administering an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent to a subject in need thereof, wherein the subject has previously received CAR-T therapy. In some embodiments, the present invention relates to a method of treating a subject with relapsed and / or refractory LBCL by administering an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent to a subject in need thereof, wherein the subject has not previously received CAR-T therapy. In some embodiments, the present invention relates to an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in the treatment of relapsed and / or refractory B-ALL.
[0105] In some embodiments, the B cell malignancy is chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL), such as relapsed and / or refractory CLL / SLL.
[0106] In some embodiments, the B cell malignancy is marginal zone lymphoma (MZL).
[0107] In some embodiments, the B cell malignancy is extranodal marginal zone lymphoma (EMZL).
[0108] In some embodiments, the B cell malignancy is nodal marginal zone B cell lymphoma (NZML).
[0109] In some embodiments, the B cell malignancy is splenic marginal zone B cell lymphoma (SMZL).
[0110] Refractory or relapsed CD19-positive B-ALL may include at least one of the following:
[0111] i) After at least 2 or more lines of systemic therapy
[0112] ii) relapse or refractory at any time after first salvage therapy, or refractory relapse.
[0113] iii) Relapse at any time after hematopoietic stem cell transplantation (HSCT)
[0114] iv) Refractory or intolerant to SOC treatment options (including blinatumomab and inotuzumab), or unsuitable / unable to receive SOC treatment options
[0115] v) Patients have R / R B-ALL Ph+ disease and are intolerant or refractory to available tyrosine kinase inhibitors (TKIs)
[0116] Endpoints and / or treatments may be measured based on one or more of the following criteria:
[0117] 1) The incidence and severity of dose-limiting toxicities (DLTs) (e.g., after 28 or 35 days, depending on the dosing schedule)
[0118] 2) The incidence and severity of adverse events (AEs) and severe adverse events (SAEs) (e.g. after 21 months)
[0119] 3) Frequency of dose interruptions (e.g. after 21 months)
[0120] 4) Frequency of dose reduction (e.g. after 21 months)
[0121] 5) Dose intensity (e.g. after 21 months)
[0122] Additionally, endpoints and / or treatments may be measured according to one or more of the following criteria:
[0123] 1) Overall response rate (ORR) (e.g. after 21 months)
[0124] 2) Complete response rate (CR) (e.g. after 21 months)
[0125] 3) Best overall response (BOR) (e.g. after 21 months)
[0126] 4) Duration of response (DOR) (e.g. after 21 months)
[0127] 5) Overall survival (OS) (e.g. after 33 months)
[0128] 6) Progression-free survival (PFS) (e.g. after 21 months)
[0129] 7) Event-free survival (EFS) (e.g. after 21 months)
[0130] 8) Maximum concentration of CD19TSP1 (Cmax) (e.g. after 21 months)
[0131] 9) Area under the curve (AUC) of CD19TSP1 (e.g. after 21 months)
[0132] 10) Trough concentration of CD19TSP1 (Ctrough) (e.g. after 21 months)
[0133] 11) Prevalence of anti-drug antibodies (ADA) (e.g., at baseline)
[0134] 12) The incidence of anti-drug antibodies (ADA) during treatment (e.g. after 21 months)
[0135] Treatment may improve one or more of the following criteria:
[0136] i) Remission rate
[0137] ii) Duration of remission
[0138] iii) Overall survival
[0139] with acceptable safety features.
[0140] In some embodiments, one or more of the following agents may be administered after an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent selected from the group consisting of: tocilizumab, siltuximab, cyclophosphamide, anti-thymocyte globulin (ATG), alemtuzumab, anakinra, steroids, anti-IL-6, anti-TNF and anti-IL-1R antibodies, antihistamines, steroids (including corticosteroids), canakinumab. For example, the steroid may be prednisone or dexamethasone. In some embodiments, an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may be administered after or concurrently with acetaminophen and / or diphenhydramine. In some embodiments, an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may be administered before, after, or concurrently with CRS therapy.
[0141] Pharmaceutical compositions and combined administration
[0142] The anti-CD19 x anti-CD3 x anti-CD2 trispecific agent can be formulated as a pharmaceutical composition containing one or more pharmaceutically acceptable excipients or carriers. In order to prepare a pharmaceutical or sterile composition, the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent formulation can be combined with one or more pharmaceutically acceptable excipients and / or carriers. These compositions can be in a variety of forms. These include, for example, liquid, semisolid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, liposomes and suppositories. The preferred form depends on the intended mode of administration and therapeutic application. Typical preferred compositions are in the form of injectable or infusible solutions. The preferred mode of administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular). In a preferred embodiment, the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent is administered by intravenous infusion or injection. In a preferred embodiment, the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent is administered by subcutaneous injection. The therapeutic composition should typically be sterile and stable under manufacturing and storage conditions. The composition can be formulated as a solution, microemulsion, dispersion, liposome or other ordered structure suitable for high antibody concentration. Sterile injectable solutions can be prepared by incorporating the active compound (i.e., antibody or antibody portion) in the desired amount into a suitable solvent followed by filtration sterilization. Pharmaceutical compositions for use in the disclosed methods can be prepared in a conventional manner. Antibodies are now widely used as active ingredients in pharmaceuticals, including products (Trastuzumab), (rituximab), (Palivizumab) and the like. The technology for lyophilizing antibodies, preparing aqueous formulations and purifying to pharmaceutical grade is well known in the art. Antibodies are typically formulated into aqueous forms for parenteral administration or formulated into lyophilized products for reconstitution with a suitable diluent before administration. In some embodiments of the disclosed methods and uses, the antibodies of the present invention are formulated into lyophilized products. Suitable lyophilized formulations can be reconstituted in a small liquid volume (e.g., 2 ml or less) to allow subcutaneous administration, and solutions with low levels of antibody aggregation can be provided. For immediate administration, it is dissolved in a suitable aqueous carrier, such as sterile water for injection or sterile buffered saline. If it is considered desirable to constitute a larger volume of solution for administration by infusion rather than bolus injection, it may be advantageous to mix human serum albumin or the patient's own heparinized blood into saline during formulation. The presence of an excess of such physiologically inert proteins prevents the loss of antibodies by adsorption to the walls of the container and the tubing used for the infusion solution. If albumin is used, a suitable concentration is from 0.5% to 4.5% by weight of the saline solution.
[0143] Application method and rate
[0144] The trispecific agents disclosed herein can be administered by a variety of methods known in the art, but for many therapeutic applications, the preferred route / mode of administration is intravenous injection or infusion. See, e.g., Sachs et al., Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example, Clin. Cancer Res; 22(6) 2016; Bai et al., A Guide to Rational Dosing of Monoclonal Antibodies, Clin. Pharmacokinet. 2012: 51(2) 119-135; Le Tourneau, J., Dose Escalation Methods in Phase I Cancer Clinical Trials, J Natl Cancer Inst 2009; 101: 708-720; Wang, D. et al., Fixed Dosing Versus Body Size-Based Dosing of Monoclonal Antibodies in Adult Clinical Trials [Fixed versus Weight-Based Dosing of Monoclonal Antibodies in Adult Clinical Trials], J Clin Pharmacol [Journal of Clinical Pharmacology] 2009; 29: 1012-1024; Hempel, G. et ano, Flat-Fixed Dosing Versus Body Surface Aread-Based Dosing of Anticancer Drugs: There Is a Difference [Fixed Dosing of Anticancer Drugs Versus Body Surface Aread-Based Dosing: There Is a Difference], The Oncologist [Oncologist] 2007: 12: 924-926, Mathijssen, R.Flat-Fixed Dosing Versus Body Surface Area-Based Dosing of Anticancer Drugs in Adults: Does It Make a Difference? ], The Oncologist, 2007; 12:913-923; Leveque, Evaluation of Fixed Dosing of New Anticancer Agents in Phase I Studies, Anticancer Research 28:300275-2078 (2008), Gurney, How to calculate the dose of chemotherapy, British Journal of Cancer (2002) 86, 1297-1302; For example, the antibody molecule can be administered by intravenous infusion at a rate of more than 20 mg / min, such as 20-40 mg / min, and typically greater than or equal to 40 mg / min, to achieve a dose of about 35 to 440 mg / m2, typically about 70 to 310 mg / m2 and more typically about 110 to 130 mg / m2. In an embodiment, the antibody molecule can be administered by intravenous infusion at a rate of less than 10 mg / min; preferably less than or equal to 5 mg / min, to achieve a dose of about 1 to 100 mg / m2, preferably about 5 to 50 mg / m2, about 7 to 25 mg / m2, and more preferably about 10 mg / m2. The route and / or mode of administration will vary depending on the desired results.
[0145] Dosage regimen
[0146] The dosage regimen is adjusted to provide the optimal desired response (e.g., a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is particularly advantageous to formulate parenteral compositions in dosage unit form for ease of administration and to achieve uniformity of dosage. As used herein, a dosage unit form refers to a physically discrete unit suitable as a unit dose for a subject to be treated; each unit contains a predetermined amount of active compound calculated to produce the desired therapeutic effect in combination with a desired pharmaceutical carrier. The specifications of the dosage unit forms of the present invention are specified by and directly depend on: (a) the unique characteristics of the active compound and the specific therapeutic effect to be achieved, and (b) the inherent limitations in the field of compounding such active compounds for treating the sensitivity of individuals.
[0147] 5. Other Embodiments
[0148] All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.
[0149] Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
[0150] 6. Other Embodiments
[0151] Example 1
[0152] Developed in vitro RTCC assay to prove CD19TSP1-mediated CD19+B cell lymphoma cell line Karpas422 specific lysis.Karpas422 cells are engineered to overexpress firefly luciferase gene.After Karpas422 cells are co-cultured with T cells in the presence of CD19TSP1 or isotype control antibody TSP1C (which has anti-chicken lysozyme part but not CD19 binding part, i.e., antibody targeting anti-chicken lysozyme xCD2xCD3), tumor cell killing, T cell proliferation and cytokine secretion are assessed.Then measure the luciferase signal reduction as an indicator of Karpas422 cell lysis.In addition, T cell activation is assessed by quantitatively producing levels of interferon gamma (IFNγ), interleukin-2 (IL-2) and tumor necrosis factor alpha (TNFα) cytokines in the culture supernatant, and T cell proliferation is determined using T cell counting from flow cytometry.
[0153] T cells from healthy donors were co-cultured with luciferase-expressing Karpas422 cells at a 1:1 ratio in the presence of CD19TSP1 or TSP1C for 96 hours. % Killing (% lysis of Karpas 422 cells) was determined by the reduction in luciferase activity compared to Karpas422 cells alone. Mean + / - SEM is plotted from twelve biological replicates (from four individual healthy donor T cells, each replicated in three independent experiments). See Figure 2 .
[0154] CD19TSP1 at doses above 0.01 nM mediated efficient killing of Karpas 422 cells by T cells from healthy human donors in a dose-dependent manner, whereas the isotype control antibody (TSP1C) showed only negligible killing at 1 nM, the highest concentration tested.
[0155] T cell proliferation was quantified using flow cytometry.
[0156] CTV-stained T cells from healthy donors were co-cultured with luciferase-expressing Karpas422 cells at a 1:1 ratio for 96 hours in the presence of the indicated concentrations of CD19TSP1 or TSP1C. T cell counts were determined using flow cytometry by gating on CTV-stained T cells. Means + / - SEM are plotted from twelve biological replicates (from four individual healthy donor T cells, each replicated in three independent experiments). See Figure 3 .
[0157] CD19TSP1 induced a concentration-dependent T cell proliferation in the presence of Karpas 422 cells. As expected, T cells in the TSP1C control showed no proliferation.
[0158] CD19TSP1 treatment results in secretion of IFNγ, IL-2, and TNFα by Karpas422-T cell co-cultures. Cell culture supernatants were collected from the RTCC assay 48 hours after the start of Karpas422-T cell co-culture. Secreted IFNγ, IL-2, and TNFα levels were quantified using the Custom3-Plex MSD VPLEX immunoassay. Mean values + / - SEM are plotted from twelve biological replicates (T cells from four individual healthy donors, each replicated in three independent experiments). See Figure 4 .
[0159] Meso Scale Discovery (MSD) VPLEX multiplex immunoassay was used to quantify the levels of IFNγ, IL-2, and TNFα in the conditioned medium determined by RTCC. CD19TSP1 treatment of Karpas422 and T cell co-cultures resulted in increased secretion of IFNγ, IL-2, and TNFα, while TSP1C induced no to low levels of secretion (data not shown). The magnitude of secreted IFNγ was significantly higher than that of IL-2 and TNFα.
[0160] Example 2
[0161] Two preclinical in vivo models were used to evaluate the activity of CD19TSP1: the AdT model and the hCD34+ model. The AdT model was used to evaluate the single-dose activity of CD19TSP1 across a dose range against established DLBCL tumors. The hCD34+ model was used in a CD19TSP1 multiple-dose study against established DLBCL tumors. In both model systems, CD19TSP1 demonstrated robust and durable anti-tumor responses against the same established tumors.
[0162] CD19TSP1 showed dose-dependent antitumor activity and was well tolerated in the AdT model with DLBCL xenografts: 5x 106OCILY19 cells were implanted subcutaneously (sc) on day 0. Two days later, 15 million PBMCs from frozen donor reserves were implanted via IV administration. Eleven days after tumor implantation, the tumor volume reached approximately 200mm3, and the animals were randomly assigned to their corresponding treatment groups and received a single dose of their corresponding treatment. The antitumor activity of CD19TSP1 was evaluated at different dose levels. Tumor groups only (in mice without human PBMC adoptive transfer) and tumors in AdT mice (without Ab) were included as controls. CD19TSP1 administered at 0.3mg / kg, 0.1mg / kg and 0.03mg / kg showed antitumor activity that was statistically different from that of the control group (p<0.05, one-way ANOVA and post-hoc Dunnetts multiple comparisons). The number of CR, PR and NR in each group is as follows: 0.3mg / kg (7CR / 0PR / 1NR), 0.1mg / kg (2CR / 6PR / 0NR) and 0.03mg / kg (2CR / 5PR / 1NR), 0.01mg / kg (1CR / 3PR / 4NR) and 0.003mg / kg (0CR / 7PR / 1NR). CR = complete remission; PR = partial remission; NR = no response.
[0163] CD19TSP1 showed dose-dependent antitumor activity and durable responses against DLBCL xenografts in the hCD34+ model: 5x 10 6 OCILY19 cells. 11 days after implantation, animals were randomly assigned to the following corresponding treatment groups based on tumor size and donor: no treatment, 0.3mg / kg CD19TSP1 or 0.1mg / kg CD19TSP1. Animals were treated once a week via IV dose (QW x 3, IV) for 3 weeks. CD19TSP1 showed dose-dependent activity. Compared with the control, 0.3mg / kg and 0.1mg / kg CD19TSP1 both showed statistically significant antitumor activity (p<0.05, one-way ANOVA and post-hoc SIDAK multiple comparisons). CD19TSP1 administered at 0.3mg / kg showed robust activity (5 / 8CR and 1PR), while 0.1mg / kg caused growth delay and lower activity (1CR and 1PR). Compared with untreated, 0.1mg / kg and 0.3mg / kg both conferred survival benefits. CR = complete resolution; PR = partial resolution.
[0164] Example 3
[0165] Evaluation of CD19TSP1 in a dose-ranging toxicity study in cynomolgus monkeys demonstrated that single and repeated (2 doses given one week apart) intravenous administration of CD19TSP1 was tolerable. Total B cell counts were measured in peripheral blood in monkeys treated with a single dose (Phase I) or two doses (Phase II) of CD19TSP1 or a trispecific isotype control TSP1C (which has an anti-chicken lysozyme portion instead of a CD19 binding portion, i.e., an antibody targeting anti-chicken lysozyme xCD2xCD3). Intravenous administration of CD19TSP1 induced a decrease in peripheral blood (see Figure 6 ) and sustained B-cell depletion in lymphoid organs (based on histopathological evaluation).
[0166] Example 4
[0167] CD19TSP1 was also tolerated after a single subcutaneous dose (0.3 mg / kg) in cynomolgus monkeys.
[0168] Example 5
[0169] Disclosed herein is a Phase I study to characterize the safety and tolerability of an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent (CD19TSP1) and identify the maximum tolerated dose and / or recommended dose, administration schedule and route in R / RB cell NHL and / or R / R B-ALL. The study includes a dose escalation portion of an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent (CD19TSP1) in R / RB cell NHL and / or R / R B-ALL, and a dose expansion portion in R / R LBCL that i) received CAR-T therapy or ii) did not receive CAR-T therapy and iii) R / R B-ALL. During the dose escalation period, the safety (including dose-dose limiting toxicity (DLT) relationship) and tolerability of the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent (CD19TSP1) will be evaluated, and one or more schedules, one or more administration routes, and one or more doses for use in the expansion portion will be identified based on a review of these data. The recommended dose will also be guided by available information on pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity. Dose escalation will be guided by an adaptive Bayesian logistic regression model (BLRM) following the principles of dose escalation with overdose control (EWOC). Different schedules (once a week (Q1W) or once every two weeks (Q2W), with and without priming doses) and routes of administration (intravenous (iv) or subcutaneous (sc)) will be explored in the dose escalation groups.
[0170] The anti-CD19 x anti-CD3 x anti-CD2 trispecific agent (CD19TSP1) will be used for adult NHL patients who have failed two or more chemotherapies and have progressed (or relapsed) after autologous hematopoietic stem cell transplant (HSCT), or who are not suitable for or do not consent to this procedure.
[0171] The anti-CD19 x anti-CD3 x anti-CD2 trispecific agent (CD19TSP1) will be used in adult patients with R / R ALL.
[0172] The anti-CD19 x anti-CD3 x anti-CD2 trispecific agent (CD19TSP1) will be used in adult R / R LBCL (DLBCL, double / triple hit HGBCL, PMBCL, FL3B patients who have not received CAR-T therapy targeting CD19).
[0173] The anti-CD19 x anti-CD3 x anti-CD2 trispecific agent (CD19TSP1) will be used in adult patients with R / R LBCL (DLBCL, double / triple hit HGBCL, PMBCL, FL3B) who have not received CAR-T therapy targeting CD19.
[0174] The anti-CD19 x anti-CD3 x anti-CD2 trispecific agent (CD19TSP1) will be used in adult patients with R / R ALL.
[0175] The incidence and severity of dose-limiting toxicities will be used as a safety assessment of the study drug. Dose-limiting toxicities are defined as adverse events or abnormal laboratory values of CTCAE grade 3 or higher that occur within the DLT evaluation period (28 days for the initial treatment schedule or 35 days for the priming dose schedule) and are not primarily related to disease, disease progression, intercurrent illness, or concomitant medications.
[0176] For NHL, overall response rate (ORR), complete response rate (CR), best overall response rate (BOR), duration of response (DOR), overall survival (OS), progression-free survival (PFS), event-free survival (EFS) will be based on the Lugano response Criteria Classification criteria and for ALL, based on the National Comprehensive Cancer Network (NCCN) guidelines, as relevant.
[0177] Incorporated by Reference
[0178] All publications, patents, and accession numbers mentioned herein are hereby incorporated by reference in their entirety to the same extent as if each individual publication or patent was specifically and individually indicated to be incorporated by reference.
[0179] Equivalent
[0180] Although specific embodiments of the present invention have been discussed, the above description is illustrative and not restrictive. Many variations of the present invention will become apparent to those skilled in the art after reviewing this specification and the following claims. The full scope of the present invention should be determined by reference to the full scope of the claims and their equivalents and the specification together with such variations.
Claims
1. A method of treating a subject suffering from a condition of non-Hodgkin lymphoma (NHL) or acute lymphoblastic leukemia (ALL) by administering to a subject in need thereof a therapeutically effective amount of an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent, wherein optionally the NHL or ALL may be relapsed and / or refractory NHL or relapsed and / or refractory ALL.
2. An anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use in treating a condition of non-Hodgkin lymphoma (NHL) or acute lymphoblastic leukemia (ALL), wherein optionally the NHL or ALL may be relapsed and / or refractory NHL or relapsed and / or refractory ALL.
3. The method of claim 1 or the trispecific agent for use of claim 2, wherein the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent comprises (a) a first polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO: 37; (b) a second polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO: 38; and (c) a third polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:
39.
4. The method of claim 1 or 3 or the trispecific agent for use according to claim 2 or 3, wherein the disorder is selected from the group consisting of LBCL, DLBCL, HGBCL, PMBCL, FL, FL3B, MCL, SLL, MZL and ALL, wherein optionally the disorder may be relapsed and / or refractory.
5. The method of any one of claims 1 or 3 to 4 or the trispecific agent for use of any one of claims 2 to 4, wherein the disorder is selected from the group consisting of: DLBCL, HGBCL, PMBCL, FL3B, MCL, SLL and MZL, wherein optionally the disorder may be relapsed and / or refractory.
6. The method of any one of claims 1 or 3 to 5 or the trispecific agent for use of any one of claims 2 to 5, wherein the disorder is R / R DLBCL, optionally wherein it is de novo or transformed R / R DLBCL.
7. The method of any one of claims 1 or 3 to 6 or the trispecific agent for use of any one of claims 2 to 6, wherein the disorder is R / R HGBCL, optionally wherein it is relapsed and / or refractory double / triple hit high grade B-cell lymphoma (HGBCL).
8. The method of any one of claims 1 or 3 to 7 or the trispecific agent for use as described in any one of claims 2 to 7, wherein the treatment may be after a previous CAR-T therapy and / or after treatment with a chemotherapy regimen containing a CD20 monoclonal antibody and / or before autologous hematopoietic stem cell transplantation (HSCT).
9. The method of any one of claims 1 or 3 to 8 or the trispecific agent for use according to any one of claims 2 to 8, wherein the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent can be administered Q1W or Q2W.
10. The method of any one of claims 1 or 3 to 9 or the trispecific agent for use of any one of claims 2 to 9, wherein the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent can be administered intravenously or subcutaneously.
11. The method of any one of claims 1 or 3 to 10 or the trispecific agent for use of any one of claims 2 to 10, wherein the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent can be administered via an initial priming dose followed by a main dose.
12. The method of any one of claims 1 or 3 to 11 or the trispecific agent for use of any one of claims 2 to 11, wherein the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent is administered at a dose selected from the group consisting of 0.1, 0.3, 1, 3, 10, 20, 40, 80, 160, 320, 640, 1280, 2560 micrograms per kilogram (μg / kg).
13. The method of any one of claims 1 or 3 to 12 or the trispecific agent for use of any one of claims 2 to 12, wherein the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may be administered before, after or concurrently with CRS therapy.
14. The method of any one of claims 1 or 3 to 13 or the trispecific agent for use according to any one of claims 2 to 13, wherein the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may be administered before, after or simultaneously with tocilizumab.
15. A method of treating a subject having a CD19-related disease or disorder, the method comprising administering an anti-CD19 x anti-CD3 x anti-CD2 trispecific agent at a dose selected from the group consisting of 0.1, 0.3, 1, 3, 10, 20, 40, 80, 160, 320, 640, 1280, 2560 micrograms / kilogram (μg / kg).
16. An anti-CD19 x anti-CD3 x anti-CD2 trispecific agent for use as a medicament, wherein the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent is administered at a dose selected from the group consisting of 0.1, 0.3, 1, 3, 10, 20, 40, 80, 160, 320, 640, 1280, 2560 micrograms per kilogram (μg / kg).
17. The method of any one of claims 1 or 3 to 15 or the trispecific agent for use of any one of claims 2 to 14 and 16, wherein the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent may comprise a CD19 binding portion wherein CDR-H1, CDR-H2 and CDR-H3 have the amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, and CDR-L1, CDR-L2 and CDR-L3 have the amino acid sequences of SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO:
19.
18. The method of any one of claims 15 or 17 or the trispecific agent for use of any one of claims 16 to 17, wherein the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent comprises (a) a first polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO: 37; (b) a second polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO: 38; and (c) a third polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:
39.
19. The method of any one of claims 1 or 3 to 15 or 17 to 18 or the trispecific agent for use of any one of claims 2 to 14 or 16 to 18, wherein the condition or CD19-associated disease or disorder is LBCL or FL3B, optionally relapsed and / or refractory LBCL or FL3B.
20. The method of any one of claims 15 or 17 to 18 or the trispecific agent for use of any one of claims 16 to 18, wherein the disease or disorder is systemic lupus erythematosus (SLE).
21. The method of any one of claims 15 or 17 to 20 or the trispecific agent for use of any one of claims 16 to 20, wherein the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent can be administered Q1W or Q2W.
22. The method of any one of claims 15 or 17 to 21 or the trispecific agent for use of any one of claims 16 to 21, wherein the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent can be administered intravenously or subcutaneously.
23. The method of any one of claims 15 or 17 to 22 or the trispecific agent for use of any one of claims 16 to 22, wherein the anti-CD19 x anti-CD3 x anti-CD2 trispecific agent can be administered via an initial priming dose followed by a main dose.
Citation Information
Patent Citations
Middle threaded fitting
US10571062B2
Low pH hydrophobic interaction chromatography for antibody purification
US5641870A
Artificial antibody polypeptides
US6703199B1
CD19 binding molecules and uses thereof
WO2020236792A1
